mCapOX plus cetuximab

DRUG2 trials

Sponsors

West China Hospital, Meng Qiu

Conditions

CapecitabineCetuximabColo-rectal CancerColorectal Cancer (CRC)

Phase 2

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

RecruitingNCT05022030

West China HospitalCapecitabine, Cetuximab, Colo-rectal Cancer

Start: 2021-07-21End: 2026-06-01Target: 150Updated: 2024-03-07

Phase 3

First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study

Not yet recruitingNCT06616259

Meng QiuCapecitabine, Cetuximab, Colorectal Cancer (CRC)

Start: 2024-09-26End: 2029-09-30Target: 452Updated: 2024-09-27

Related Papers

A multicenter randomized phase II trial assessing the efficacy and safety of mCapOX plus cetuximab with mFOLFOX6 plus cetuximab as first-line treatment for <i>RAS/BRAF</i> wild-type metastatic colorectal cancer: Updated results from the CAPCET study.

Journal of Clinical Oncology2026-05-27

A multicenter randomized phase II trial assessing the efficacy and safety of mCapOX plus cetuximab and mFOLFOX6 plus cetuximab as first-line treatment for patients with RAS/BRAF wild-type metastatic colorectal cancer: Primary results of the CAPCET study.

Journal of Clinical Oncology2025-05-28